Skip to main content
Top
Published in: Journal of Translational Medicine 1/2003

Open Access 01-06-2003 | Review

Polymorphism in clinical immunology – From HLA typing to immunogenetic profiling

Authors: Ping Jin, Ena Wang

Published in: Journal of Translational Medicine | Issue 1/2003

Login to get access

Abstract

The pathology of humans, in contrast to that of inbred laboratory animals faces the challenge of diversity addressed in genetic terms as polymorphism. Thus, unsurprisingly, treatment modalities that successfully can be applied to carefully-selected pre-clinical models only sporadically succeed in the clinical arena. Indeed, pre-fabricated experimental models purposefully avoid the basic essence of human pathology: the uncontrollable complexity of disease heterogeneity and the intrinsic diversity of human beings. Far from pontificating on this obvious point, this review presents emerging evidence that the study of complex system such as the cytokine network is further complicated by inter-individual differences dictated by increasingly recognized polymorphisms. Polymorphism appears widespread among genes of the immune system possibly resulting from an evolutionary adaptation of the organism facing an ever evolving environment. We will refer to this high variability of immune-related genes as immune polymorphism. In this review we will briefly highlight the possible clinical relevance of immune polymorphism and suggest a change in the approach to the study of human pathology, from the targeted study of individual systems to a broader view of the organism as a whole through immunogenetic profiling.
Appendix
Available only for authorised users
Literature
1.
go back to reference Klein J: Natural history of the major histocompatibility complex. 1986, New York: John Wiley & Sons, 1 Klein J: Natural history of the major histocompatibility complex. 1986, New York: John Wiley & Sons, 1
2.
go back to reference Bodmer WF: HLA: what's in a name? A commentary on HLA nomenclature development over the years. Tissue Antigens. 1997, 46: 293-296. Bodmer WF: HLA: what's in a name? A commentary on HLA nomenclature development over the years. Tissue Antigens. 1997, 46: 293-296.
3.
go back to reference Dawkins RL, Degli-Esposti MP, Abraham LJ, Zhang W, Christiansen FT: Conservation versus polymorphism of the MHC in relation to transplantation, immune responses and autoimmune disease. In Molecular evolution of the major histocompatibility complex. Edited by: Klein J, Klein D. 1991, Berlin: Springer-Verlag, 391-402. Dawkins RL, Degli-Esposti MP, Abraham LJ, Zhang W, Christiansen FT: Conservation versus polymorphism of the MHC in relation to transplantation, immune responses and autoimmune disease. In Molecular evolution of the major histocompatibility complex. Edited by: Klein J, Klein D. 1991, Berlin: Springer-Verlag, 391-402.
4.
go back to reference Bjorkman PJ, Parham P: Structure, function, and diversity of class I major histocompatibility complex molecules. Annu Rev Biochem. 1990, 59: 253-288. 10.1146/annurev.bi.59.070190.001345.PubMed Bjorkman PJ, Parham P: Structure, function, and diversity of class I major histocompatibility complex molecules. Annu Rev Biochem. 1990, 59: 253-288. 10.1146/annurev.bi.59.070190.001345.PubMed
5.
go back to reference Parham P: The pros and cons of polymorphism: a brighter future for cheetahs?. Res Immunol. 1991, 142: 447-448. 10.1016/0923-2494(91)90045-K.PubMed Parham P: The pros and cons of polymorphism: a brighter future for cheetahs?. Res Immunol. 1991, 142: 447-448. 10.1016/0923-2494(91)90045-K.PubMed
6.
go back to reference Adams EJ, Parham P: Species-specific evolution of MHC class I genes in the higher primates. Immunol Rev. 2001, 183: 41-64. 10.1034/j.1600-065x.2001.1830104.x.PubMed Adams EJ, Parham P: Species-specific evolution of MHC class I genes in the higher primates. Immunol Rev. 2001, 183: 41-64. 10.1034/j.1600-065x.2001.1830104.x.PubMed
7.
go back to reference Bettinotti M, Kim CJ, Lee K-H, Roden M, Cormier JN, Panelli MC: Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy. J Immunol. 1998, 161: 877-889.PubMed Bettinotti M, Kim CJ, Lee K-H, Roden M, Cormier JN, Panelli MC: Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy. J Immunol. 1998, 161: 877-889.PubMed
8.
go back to reference Krausa P, Brywka M, Savage D, Hui KM, Bunce M, Ngai JL: Genetic polymorphism within HLA-A*02: significant allelic variation revealed in different populations. Tissue Antigens. 1995, 45: 223-231.PubMed Krausa P, Brywka M, Savage D, Hui KM, Bunce M, Ngai JL: Genetic polymorphism within HLA-A*02: significant allelic variation revealed in different populations. Tissue Antigens. 1995, 45: 223-231.PubMed
9.
go back to reference Browning M, Krausa P: Genetic diversity of HLA-A2: evolutionary and functional significance. Immunol Today. 1996, 17: 165-170. 10.1016/0167-5699(96)80614-1.PubMed Browning M, Krausa P: Genetic diversity of HLA-A2: evolutionary and functional significance. Immunol Today. 1996, 17: 165-170. 10.1016/0167-5699(96)80614-1.PubMed
10.
go back to reference Player MA, Barracchini KC, Simonis TB, Rivoltini L, Arienti F, Castelli C: Differences in frequency distribution of HLA-A2 sub-types between American and Italian Caucasian melanoma patients: relevance for epitope specific vaccination protocols. J Immunother. 1996, 19: 357-363. Player MA, Barracchini KC, Simonis TB, Rivoltini L, Arienti F, Castelli C: Differences in frequency distribution of HLA-A2 sub-types between American and Italian Caucasian melanoma patients: relevance for epitope specific vaccination protocols. J Immunother. 1996, 19: 357-363.
11.
go back to reference Adams SD, Barracchini KC, Simonis TB, Stroncek D, Marincola FM: High throughput HLA sequence-based typing utilizing the ABI prism 3700 analyzer. Tumori. 2001, 87: s41-s44. Adams SD, Barracchini KC, Simonis TB, Stroncek D, Marincola FM: High throughput HLA sequence-based typing utilizing the ABI prism 3700 analyzer. Tumori. 2001, 87: s41-s44.
12.
go back to reference Miguelse S, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, Martino L: HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term non-progressors. Proc Natl Acad Sci U S A. 2000, 97: 2709-2714. 10.1073/pnas.050567397. Miguelse S, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, Martino L: HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term non-progressors. Proc Natl Acad Sci U S A. 2000, 97: 2709-2714. 10.1073/pnas.050567397.
13.
go back to reference Kaufman J, Volk H, Wallny HJ: A "minimal essential MHC" and an "unrecognized MHC": two extremes in selection for polymorphism. Immunol Rev. 143: 63-88. 2-1-1995. Ref Type: Journal (Full) Kaufman J, Volk H, Wallny HJ: A "minimal essential MHC" and an "unrecognized MHC": two extremes in selection for polymorphism. Immunol Rev. 143: 63-88. 2-1-1995. Ref Type: Journal (Full)
14.
go back to reference Rivoltini L, Loftus DJ, Barracchini K, Arienti F, Mazzocchi A, Biddison WE: Binding and presentation of peptides derived from melanoma antigens MART-1 and gp100 by HLA-A2 subtypes: implications for peptide-based immunotherapy. J Immunol. 1996, 156: 3882-3891.PubMed Rivoltini L, Loftus DJ, Barracchini K, Arienti F, Mazzocchi A, Biddison WE: Binding and presentation of peptides derived from melanoma antigens MART-1 and gp100 by HLA-A2 subtypes: implications for peptide-based immunotherapy. J Immunol. 1996, 156: 3882-3891.PubMed
15.
go back to reference Kim CJ, Parkinson DR, Marincola FM: Immunodominance across the HLA polymorphism: implications for cancer immunotherapy. J Immunother. 1997, 21: 1-16. Kim CJ, Parkinson DR, Marincola FM: Immunodominance across the HLA polymorphism: implications for cancer immunotherapy. J Immunother. 1997, 21: 1-16.
16.
go back to reference McCluskey J, Peh CA: The human leucocyte antigens and clinical medicine: an overview. Rev Immunogenetics. 1999, 1: 3-20. McCluskey J, Peh CA: The human leucocyte antigens and clinical medicine: an overview. Rev Immunogenetics. 1999, 1: 3-20.
17.
go back to reference Erlich HA: HLA class II sequences and genetic susceptibility to insulin dependent diabetes mellitus. Baillieres Clin Endocrinol Metab. 1999, 5: 395-411. Erlich HA: HLA class II sequences and genetic susceptibility to insulin dependent diabetes mellitus. Baillieres Clin Endocrinol Metab. 1999, 5: 395-411.
18.
go back to reference Hildesheim A, Apple RJ, Chen C-J, Wang SS, Cheng Y-J, Klitz W: Association of HLA class I and II alleles and extended haplotypes with nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst. 2002, 94: 1780-1789. 10.1093/jnci/94.23.1780.PubMed Hildesheim A, Apple RJ, Chen C-J, Wang SS, Cheng Y-J, Klitz W: Association of HLA class I and II alleles and extended haplotypes with nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst. 2002, 94: 1780-1789. 10.1093/jnci/94.23.1780.PubMed
19.
go back to reference Luppi P, Alexander A, Bartera S, Noonan K, Trucco M: The same HLA-DQ alleles determine either susceptibility or resistance to different coxsackievirus-mediated autoimmune diseases. J Biol Regul Homeost Agents. 1999, 13: 14-26.PubMed Luppi P, Alexander A, Bartera S, Noonan K, Trucco M: The same HLA-DQ alleles determine either susceptibility or resistance to different coxsackievirus-mediated autoimmune diseases. J Biol Regul Homeost Agents. 1999, 13: 14-26.PubMed
20.
go back to reference Chan SH, Day NE, Kunaratnam N, Chia KB, Simons MJ: HLA and nasopharyngeal carcinoma in Chinese – a further study. Int J Cancer. 1983, 32: 171-176.PubMed Chan SH, Day NE, Kunaratnam N, Chia KB, Simons MJ: HLA and nasopharyngeal carcinoma in Chinese – a further study. Int J Cancer. 1983, 32: 171-176.PubMed
21.
22.
go back to reference Ehrlich R, Lemonnier FA: HFE – a novel nonclassical class I molecule that is involved in iron metabolism. Immunity. 2000, 13: 585-588.PubMed Ehrlich R, Lemonnier FA: HFE – a novel nonclassical class I molecule that is involved in iron metabolism. Immunity. 2000, 13: 585-588.PubMed
23.
go back to reference Louka AS, Sollid LM: HLA in coeliac disease: unravelling the complex genetics of a complex disorder. Tissue Antigens. 2003, 61: 105-117.PubMed Louka AS, Sollid LM: HLA in coeliac disease: unravelling the complex genetics of a complex disorder. Tissue Antigens. 2003, 61: 105-117.PubMed
24.
go back to reference Trucco M, LaPorte R: Exposure to superantigens as an immunogenetic explanation of type I diabetes mini-epidemics. J Pediatr Endocrinol Metab. 1995, 8: 3-10.PubMed Trucco M, LaPorte R: Exposure to superantigens as an immunogenetic explanation of type I diabetes mini-epidemics. J Pediatr Endocrinol Metab. 1995, 8: 3-10.PubMed
25.
go back to reference Trucco M: Molecular mechanisms involved in the ethiology and pathogenesis of autoimmune diseases. Clin Invest. 1992, 70: 756-765. Trucco M: Molecular mechanisms involved in the ethiology and pathogenesis of autoimmune diseases. Clin Invest. 1992, 70: 756-765.
26.
go back to reference Thomson G: HLA disease associations: models for insulin dependent diabetes mellitus and the study of complex human genetic disorders. Annu Rev Genet. 1988, 22: 31-50. 10.1146/annurev.ge.22.120188.000335.PubMed Thomson G: HLA disease associations: models for insulin dependent diabetes mellitus and the study of complex human genetic disorders. Annu Rev Genet. 1988, 22: 31-50. 10.1146/annurev.ge.22.120188.000335.PubMed
27.
go back to reference Friday RP, Trucco M, Pietropaolo M: Genetics of type 1 diabetes mellitus. Diabetes Nutr Metab. 1999, 12: 3-26.PubMed Friday RP, Trucco M, Pietropaolo M: Genetics of type 1 diabetes mellitus. Diabetes Nutr Metab. 1999, 12: 3-26.PubMed
28.
go back to reference Luppi P, Rossiello MR, Faas S, Trucco M: Genetic background and environment contribute synergistically to the onset of autoimmune diseases. J Mol Med. 1995, 73: 381-393.PubMed Luppi P, Rossiello MR, Faas S, Trucco M: Genetic background and environment contribute synergistically to the onset of autoimmune diseases. J Mol Med. 1995, 73: 381-393.PubMed
29.
go back to reference Simons MJ: HLA and nasopharyngeal carcinoma: 30 years on. ASHI Quarterly. 2003, 27: 52-55. Simons MJ: HLA and nasopharyngeal carcinoma: 30 years on. ASHI Quarterly. 2003, 27: 52-55.
30.
go back to reference Wang DG, Fan J-B, Siao C-J, Berno A, Young P, Sapolsky R: Large-scale identification, mapping and genotyping of single-nucleotide polymorphisms in the human genome. Science. 1998, 280: 1077-1082. 10.1126/science.280.5366.1077.PubMed Wang DG, Fan J-B, Siao C-J, Berno A, Young P, Sapolsky R: Large-scale identification, mapping and genotyping of single-nucleotide polymorphisms in the human genome. Science. 1998, 280: 1077-1082. 10.1126/science.280.5366.1077.PubMed
31.
go back to reference The international SNP Map Working Group: A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature. 2001, 409: 928-933. 10.1038/35057149. The international SNP Map Working Group: A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature. 2001, 409: 928-933. 10.1038/35057149.
32.
go back to reference Cooper DN, Ball EV, Krawczak M: The human gene mutation database. Nucleic Acids Res. 1998, 26: 285-287. 10.1093/nar/26.1.285.PubMedCentralPubMed Cooper DN, Ball EV, Krawczak M: The human gene mutation database. Nucleic Acids Res. 1998, 26: 285-287. 10.1093/nar/26.1.285.PubMedCentralPubMed
33.
go back to reference Ng PC, Henikoff S: Accounting for human polymorphisms predicted to affect protein function. Genome Res. 2002, 12: 436-446. 10.1101/gr.212802.PubMedCentralPubMed Ng PC, Henikoff S: Accounting for human polymorphisms predicted to affect protein function. Genome Res. 2002, 12: 436-446. 10.1101/gr.212802.PubMedCentralPubMed
34.
go back to reference Collins FS, Brooks LD, Chakravarti A: A DNA polymorphism discovery resource for research on human genetic variation. Genome Res. 1998, 8: 1229-1231.PubMed Collins FS, Brooks LD, Chakravarti A: A DNA polymorphism discovery resource for research on human genetic variation. Genome Res. 1998, 8: 1229-1231.PubMed
35.
go back to reference Schafer AL, Hawkins JR: DNA variation and the future of human genetics. Nature Biotech. 1998, 16: 33-39. 10.1038/5412. Schafer AL, Hawkins JR: DNA variation and the future of human genetics. Nature Biotech. 1998, 16: 33-39. 10.1038/5412.
36.
go back to reference Patil N, Berno AJ, Hinds DA, Barrett WA, Doshi JM, Hacker CR: Blocks of limited haplotype diversity revealed by high-resolution scanning of human chromosome 21. Science. 2001, 294: 1719-1723. 10.1126/science.1065573.PubMed Patil N, Berno AJ, Hinds DA, Barrett WA, Doshi JM, Hacker CR: Blocks of limited haplotype diversity revealed by high-resolution scanning of human chromosome 21. Science. 2001, 294: 1719-1723. 10.1126/science.1065573.PubMed
37.
go back to reference Kwok P-Y: Genetic association by whole-genome analysis. Science. 2001, 294: 2669-1670. 10.1126/science.1066921. Kwok P-Y: Genetic association by whole-genome analysis. Science. 2001, 294: 2669-1670. 10.1126/science.1066921.
38.
go back to reference Marsh SG, Albert ED, Bodmer WF, Bontrop RE, Dupont B, Erlich HA: Nomenclature for factors of the HLA system, 2002. Eur J Immunogen. 2002, 29: 463-515. 10.1046/j.1365-2370.2002.00359.x.PubMed Marsh SG, Albert ED, Bodmer WF, Bontrop RE, Dupont B, Erlich HA: Nomenclature for factors of the HLA system, 2002. Eur J Immunogen. 2002, 29: 463-515. 10.1046/j.1365-2370.2002.00359.x.PubMed
39.
go back to reference Natarajan K, Li H, Mariuzza RA, Margulies DH: MHC class I molecules, structure and function. Rev Immunogenetics. 1999, 1: 32-46. Natarajan K, Li H, Mariuzza RA, Margulies DH: MHC class I molecules, structure and function. Rev Immunogenetics. 1999, 1: 32-46.
40.
go back to reference Paul P, Rouas-Freiss N, Moreau P, Cabestre FA, Menier C, Khalil-Daher I: HLA-G, -E, -F preworkshop: tools and protocols for analysis of non-classical class I genes transcription and protein expression. Hum Immunol. 2000, 61: 1177-1195. 10.1016/S0198-8859(00)00154-3.PubMed Paul P, Rouas-Freiss N, Moreau P, Cabestre FA, Menier C, Khalil-Daher I: HLA-G, -E, -F preworkshop: tools and protocols for analysis of non-classical class I genes transcription and protein expression. Hum Immunol. 2000, 61: 1177-1195. 10.1016/S0198-8859(00)00154-3.PubMed
41.
go back to reference Stastny P: Polymorphism and antigenicity of HLA-MICA. ASHI Quarterly. 2002, 26: 64-69. Stastny P: Polymorphism and antigenicity of HLA-MICA. ASHI Quarterly. 2002, 26: 64-69.
42.
go back to reference Cerwenka A, Lanier LL: Ligands for natural killer cell receptors: redundancy or specificity. Immunol Rev. 2001, 181: 158-169. 10.1034/j.1600-065X.2001.1810113.x.PubMed Cerwenka A, Lanier LL: Ligands for natural killer cell receptors: redundancy or specificity. Immunol Rev. 2001, 181: 158-169. 10.1034/j.1600-065X.2001.1810113.x.PubMed
43.
go back to reference Wilson IA, Bjorkman PJ: Unusual MHC-like molecules: CD1, Fc receptor, the hemochromatosis gene product and viral homologs. Curr Opin Immunol. 1998, 10: 67-73. 10.1016/S0952-7915(98)80034-4.PubMed Wilson IA, Bjorkman PJ: Unusual MHC-like molecules: CD1, Fc receptor, the hemochromatosis gene product and viral homologs. Curr Opin Immunol. 1998, 10: 67-73. 10.1016/S0952-7915(98)80034-4.PubMed
44.
go back to reference Braud VM, Allan DS, O'Callaghan CA, Soderstrom K, D'Andrea A, Ogg GS: HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C [see comments]. Nature. 1998, 391: 795-799. 10.1038/35869.PubMed Braud VM, Allan DS, O'Callaghan CA, Soderstrom K, D'Andrea A, Ogg GS: HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C [see comments]. Nature. 1998, 391: 795-799. 10.1038/35869.PubMed
45.
go back to reference Lee N, Llano M, Carretero M, Ishitani A, Navarro F, Lopez-Botet M: HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci U S A. 1998, 95: 5199-5204. 10.1073/pnas.95.9.5199.PubMedCentralPubMed Lee N, Llano M, Carretero M, Ishitani A, Navarro F, Lopez-Botet M: HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci U S A. 1998, 95: 5199-5204. 10.1073/pnas.95.9.5199.PubMedCentralPubMed
46.
go back to reference Borrego F, Ulbrecht M, Weiss EH, Coligan JE, Brooks AG: Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J Exp Med. 1998, 187: 813-818. 10.1084/jem.187.5.813.PubMedCentralPubMed Borrego F, Ulbrecht M, Weiss EH, Coligan JE, Brooks AG: Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J Exp Med. 1998, 187: 813-818. 10.1084/jem.187.5.813.PubMedCentralPubMed
47.
go back to reference Garcia P, Llano M, de Heredia AB, WIllberg CB, Caparros E, Aparicio P: Human T cell receptor-mediated recognition of HLA-E. Eur J Immunol. 2002, 32: 936-944. 10.1002/1521-4141(200204)32:4<936::AID-IMMU936>3.3.CO;2-D.PubMed Garcia P, Llano M, de Heredia AB, WIllberg CB, Caparros E, Aparicio P: Human T cell receptor-mediated recognition of HLA-E. Eur J Immunol. 2002, 32: 936-944. 10.1002/1521-4141(200204)32:4<936::AID-IMMU936>3.3.CO;2-D.PubMed
48.
go back to reference Parham P: Immunogenetics of killer-cell immunoglobulin-like receptors. Tissue Antigens. 2003, 62: 194-200. 10.1034/j.1399-0039.2003.00126.x.PubMed Parham P: Immunogenetics of killer-cell immunoglobulin-like receptors. Tissue Antigens. 2003, 62: 194-200. 10.1034/j.1399-0039.2003.00126.x.PubMed
49.
go back to reference Maier S, Grzeschik M, Weiss EH, Ulbrecht M: Implications of HLA-E allele expression and different HLA-E ligand diversity for the regulation of NK cells. Hum Immunol. 2000, 61: 1059-1065. 10.1016/S0198-8859(00)00190-7.PubMed Maier S, Grzeschik M, Weiss EH, Ulbrecht M: Implications of HLA-E allele expression and different HLA-E ligand diversity for the regulation of NK cells. Hum Immunol. 2000, 61: 1059-1065. 10.1016/S0198-8859(00)00190-7.PubMed
50.
go back to reference Lopez-Botet M, Moretta L, Strominger J: NK-cell receptors and recognition of MHC class I molecules. Immunol Today. 1996, 17: 212-214. 10.1016/0167-5699(96)30009-1.PubMed Lopez-Botet M, Moretta L, Strominger J: NK-cell receptors and recognition of MHC class I molecules. Immunol Today. 1996, 17: 212-214. 10.1016/0167-5699(96)30009-1.PubMed
51.
go back to reference Mingari MC, Ponte M, Vitale C, Schiavetti F, Bertone S, Moretta L: Inhibitory receptors for HLA class I molecules on cytolytic T lymphocytes. Functional relevance and implications for anti-tumor immune responses. Int J Clin Lab Res. 1997, 27: 87-94.PubMed Mingari MC, Ponte M, Vitale C, Schiavetti F, Bertone S, Moretta L: Inhibitory receptors for HLA class I molecules on cytolytic T lymphocytes. Functional relevance and implications for anti-tumor immune responses. Int J Clin Lab Res. 1997, 27: 87-94.PubMed
52.
go back to reference Mingari MC, Moretta A, Moretta L: Regulation of KIR expression in human T cells: a safety mechanism that may impair protective T-cell responses. Immunol Today. 1998, 19: 153-157. 10.1016/S0167-5699(97)01236-X.PubMed Mingari MC, Moretta A, Moretta L: Regulation of KIR expression in human T cells: a safety mechanism that may impair protective T-cell responses. Immunol Today. 1998, 19: 153-157. 10.1016/S0167-5699(97)01236-X.PubMed
53.
go back to reference Gumperz JE, Valiante NM, Parham P, Lanier LL, Tyan D: Heterogeneous phenotypes of expression of the NKB1 natural killer cell class I receptor among individuals of different human histocompatibility leukocyte antigens types appear genetically regulated, but not linked to major histocompatibililty complex haplotype. J Exp Med. 1996, 183: 1817-1827.PubMed Gumperz JE, Valiante NM, Parham P, Lanier LL, Tyan D: Heterogeneous phenotypes of expression of the NKB1 natural killer cell class I receptor among individuals of different human histocompatibility leukocyte antigens types appear genetically regulated, but not linked to major histocompatibililty complex haplotype. J Exp Med. 1996, 183: 1817-1827.PubMed
54.
go back to reference Vilches C, Parham P: KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol. 2002, 2: 217-251. 10.1146/annurev.immunol.20.092501.134942. Vilches C, Parham P: KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol. 2002, 2: 217-251. 10.1146/annurev.immunol.20.092501.134942.
55.
go back to reference Shilling HG, Guethlein LA, Cheng NW, Gardiner CM, Rodriguez R, Tyan D: Allelic polymorphism synergizes with variable gene content to individualize human KIR genotype. J Immunol. 2002, 168: 2307-2315.PubMed Shilling HG, Guethlein LA, Cheng NW, Gardiner CM, Rodriguez R, Tyan D: Allelic polymorphism synergizes with variable gene content to individualize human KIR genotype. J Immunol. 2002, 168: 2307-2315.PubMed
56.
go back to reference Marsh SGE, Parham P, Dupont B, Geraghty DE, Trowsdale J, Middleton D: Killer-cell immunoglobulin-like receptor (KIR) nomenclature report, 2002. Tissue Antigens. 2003, 62: 79-86. 10.1034/j.1399-0039.2003.00072.x.PubMed Marsh SGE, Parham P, Dupont B, Geraghty DE, Trowsdale J, Middleton D: Killer-cell immunoglobulin-like receptor (KIR) nomenclature report, 2002. Tissue Antigens. 2003, 62: 79-86. 10.1034/j.1399-0039.2003.00072.x.PubMed
57.
go back to reference Velardi A, Ruggeri L, Moretta A, Moretta L: NK cells: a lesson from mismatched hematopoietic transplantation. Trends Immunol. 2002, 23: 438-444. 10.1016/S1471-4906(02)02284-6.PubMed Velardi A, Ruggeri L, Moretta A, Moretta L: NK cells: a lesson from mismatched hematopoietic transplantation. Trends Immunol. 2002, 23: 438-444. 10.1016/S1471-4906(02)02284-6.PubMed
58.
go back to reference van Sorge NM, van der Pol W-L, van de Winkel JGJ: FCgR polymorphisms: implications for function, disease susceptibility and immunotherapy. 2003, 61: 202- van Sorge NM, van der Pol W-L, van de Winkel JGJ: FCgR polymorphisms: implications for function, disease susceptibility and immunotherapy. 2003, 61: 202-
59.
go back to reference Lazarus R, Vercelli D, Palmer LJ, Klimecki WJ, SIlverman EK, Richter B: Single nucleotide polymorphisms in innate immunity genes: abundant variation and potential role in complex human disease. Immunol R. 2002, 190: 9-25. 10.1034/j.1600-065X.2002.19002.x. Lazarus R, Vercelli D, Palmer LJ, Klimecki WJ, SIlverman EK, Richter B: Single nucleotide polymorphisms in innate immunity genes: abundant variation and potential role in complex human disease. Immunol R. 2002, 190: 9-25. 10.1034/j.1600-065X.2002.19002.x.
60.
go back to reference Janeway CA: The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol Today. 1992, 13: 11-16. 10.1016/0167-5699(92)90198-G.PubMed Janeway CA: The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol Today. 1992, 13: 11-16. 10.1016/0167-5699(92)90198-G.PubMed
61.
go back to reference Medzhitov R, Janeway CA: Innate immunity: the virtues of a nonclonal system of recognition. Cell. 1997, 91: 295-298.PubMed Medzhitov R, Janeway CA: Innate immunity: the virtues of a nonclonal system of recognition. Cell. 1997, 91: 295-298.PubMed
62.
go back to reference Hoffmann JA, Kafatos FC, Janeway CA, Ezekowitz RA: Phylogenetic perspectives in innate immunity. Science. 1999, 284: 1313-1318. 10.1126/science.284.5418.1313.PubMed Hoffmann JA, Kafatos FC, Janeway CA, Ezekowitz RA: Phylogenetic perspectives in innate immunity. Science. 1999, 284: 1313-1318. 10.1126/science.284.5418.1313.PubMed
63.
go back to reference Janeway CA, Medzhitov R: Innate immune recognition. Annu Rev Immunol. 2002, 20: 197-216. 10.1146/annurev.immunol.20.083001.084359.PubMed Janeway CA, Medzhitov R: Innate immune recognition. Annu Rev Immunol. 2002, 20: 197-216. 10.1146/annurev.immunol.20.083001.084359.PubMed
64.
go back to reference Keen LJ: The extent and analysis of cytokine and cytokine receptor gene polymorphism. Transpl Immunol. 2002, 10: 143-146. 10.1016/S0966-3274(02)00061-8.PubMed Keen LJ: The extent and analysis of cytokine and cytokine receptor gene polymorphism. Transpl Immunol. 2002, 10: 143-146. 10.1016/S0966-3274(02)00061-8.PubMed
65.
go back to reference Turner D, Choudhury F, Reynard M, Railton D, Navarrete C: Typing of multiple single nucleotide polymorphisms in cytokine and receptor genes using SNaPshot. Hum Immunol. 2002, 63: 508-513. 10.1016/S0198-8859(02)00392-0.PubMed Turner D, Choudhury F, Reynard M, Railton D, Navarrete C: Typing of multiple single nucleotide polymorphisms in cytokine and receptor genes using SNaPshot. Hum Immunol. 2002, 63: 508-513. 10.1016/S0198-8859(02)00392-0.PubMed
66.
go back to reference McCarron SL, Edwards S, Evans PR, Gibbs R, Dearnaley DP, Dowe A: Influence of cytokine gene polymorphism on the development of prostate cancer. Cancer Res. 2002, 62: 3369-3372.PubMed McCarron SL, Edwards S, Evans PR, Gibbs R, Dearnaley DP, Dowe A: Influence of cytokine gene polymorphism on the development of prostate cancer. Cancer Res. 2002, 62: 3369-3372.PubMed
67.
go back to reference Howell WM, Turner SJ, Bateman AC, Theaker JM: IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma. Genes Immun. 2001, 2: 25-31. 10.1038/sj.gene.6363726.PubMed Howell WM, Turner SJ, Bateman AC, Theaker JM: IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma. Genes Immun. 2001, 2: 25-31. 10.1038/sj.gene.6363726.PubMed
68.
go back to reference Howell WM, Bateman AC, Turner SJ, Collins A, Theaker JM: Influence of vascular endothelial growth factor single nucleotide polymorphisms on tumour development in cutaneous malignant melanoma. Genes Immun. 2002, 3: 229-232. 10.1038/sj.gene.6363851.PubMed Howell WM, Bateman AC, Turner SJ, Collins A, Theaker JM: Influence of vascular endothelial growth factor single nucleotide polymorphisms on tumour development in cutaneous malignant melanoma. Genes Immun. 2002, 3: 229-232. 10.1038/sj.gene.6363851.PubMed
69.
go back to reference Bidwell J, Keen L, Gallagher G, Kimberly R, Huizinga T, McDermott MF: Cytokine gene polymorphism in human disease: on-line databases. Genes Immun. 1999, 1: 3-19. 10.1038/sj.gene.6363645.PubMed Bidwell J, Keen L, Gallagher G, Kimberly R, Huizinga T, McDermott MF: Cytokine gene polymorphism in human disease: on-line databases. Genes Immun. 1999, 1: 3-19. 10.1038/sj.gene.6363645.PubMed
70.
go back to reference Bidwell J, Keen L, Gallagher G, Kimberly R, Huizinga T, McDermott MF: Cytokine gene polymorphism in human disease: on-line databases, supplement 1. Genes Immun. 2001, 2: 61-70. 10.1038/sj.gene.6363733.PubMed Bidwell J, Keen L, Gallagher G, Kimberly R, Huizinga T, McDermott MF: Cytokine gene polymorphism in human disease: on-line databases, supplement 1. Genes Immun. 2001, 2: 61-70. 10.1038/sj.gene.6363733.PubMed
71.
go back to reference Vanderbroeck K, Goris A: Cytokine gene polymorphisms in multifactorial deseases: gateways to novel targets for immunotherapy?. Trends Pharmacol Sci. 2003, 24: 284-289. 10.1016/S0165-6147(03)00131-7. Vanderbroeck K, Goris A: Cytokine gene polymorphisms in multifactorial deseases: gateways to novel targets for immunotherapy?. Trends Pharmacol Sci. 2003, 24: 284-289. 10.1016/S0165-6147(03)00131-7.
72.
go back to reference Dean M, Carrington M, O'Brien SJ: Balanced polymorphism selected by genetic versus infectious human disease. Annu Rev Genomics Hum Genet. 2002, 3: 263-292. 10.1146/annurev.genom.3.022502.103149.PubMed Dean M, Carrington M, O'Brien SJ: Balanced polymorphism selected by genetic versus infectious human disease. Annu Rev Genomics Hum Genet. 2002, 3: 263-292. 10.1146/annurev.genom.3.022502.103149.PubMed
73.
go back to reference Knight JC: Functional implications of genetic variation in non-coding DNA for disease susceptibility and gene regulation. Clin Sci (Lond). 2003, 104: 493-501. 10.1042/CS20020304. Knight JC: Functional implications of genetic variation in non-coding DNA for disease susceptibility and gene regulation. Clin Sci (Lond). 2003, 104: 493-501. 10.1042/CS20020304.
74.
go back to reference Brinkmann BM, Huizinga TW, Kurban SS, van der Velde EA, Schreuder GM, Hazes JM: Tumor necrosis factor alpha gene polymorphism in rheumatoid arthritis: association with susceptibility to, or severity of, disease?. Br J Rheumatol. 1997, 36: 516-521. 10.1093/rheumatology/36.5.516. Brinkmann BM, Huizinga TW, Kurban SS, van der Velde EA, Schreuder GM, Hazes JM: Tumor necrosis factor alpha gene polymorphism in rheumatoid arthritis: association with susceptibility to, or severity of, disease?. Br J Rheumatol. 1997, 36: 516-521. 10.1093/rheumatology/36.5.516.
75.
go back to reference Lazarus M, Hajeer AH, Turner D, Sinnott P, Worthington J, Ollier WE: Genetic variation in the interleukin 10 gene promoter an systemic lupus erythematosus. J Rheumatol. 1997, 24: 2314-2317.PubMed Lazarus M, Hajeer AH, Turner D, Sinnott P, Worthington J, Ollier WE: Genetic variation in the interleukin 10 gene promoter an systemic lupus erythematosus. J Rheumatol. 1997, 24: 2314-2317.PubMed
76.
go back to reference Aksentijevich I, Galon J, Soares M, Mansfield E, Hull K, Oh HH: The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies and evidence for further genetic heterogeneity of periodic fevers. Am J Hum Genet. 2001, 69: 301-314. 10.1086/321976.PubMedCentralPubMed Aksentijevich I, Galon J, Soares M, Mansfield E, Hull K, Oh HH: The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies and evidence for further genetic heterogeneity of periodic fevers. Am J Hum Genet. 2001, 69: 301-314. 10.1086/321976.PubMedCentralPubMed
77.
go back to reference Leonard WJ: Cytokines and immunodeficiency diseases. Nat Rev Immunol. 2001, 1: 200-208. 10.1038/35105066.PubMed Leonard WJ: Cytokines and immunodeficiency diseases. Nat Rev Immunol. 2001, 1: 200-208. 10.1038/35105066.PubMed
78.
go back to reference Gilmour KC, Fujii H, Cranston T, Davies EG, Kinnon C, Gaspar HB: Defective expression of the interleukin-2/interleukin-15 receptor beta subunit leads to a natural killer cell-deficient form of severe combined immunodeficiency. Blood. 2001, 98: 877-879. 10.1182/blood.V98.3.877.PubMed Gilmour KC, Fujii H, Cranston T, Davies EG, Kinnon C, Gaspar HB: Defective expression of the interleukin-2/interleukin-15 receptor beta subunit leads to a natural killer cell-deficient form of severe combined immunodeficiency. Blood. 2001, 98: 877-879. 10.1182/blood.V98.3.877.PubMed
79.
go back to reference Du Y, Dodel RC, Eastwood BJ, Bales KR, Gao F, Lohmuller F: Association of an interleukin 1 alpha polymorphism with Alzheimer's disease. Neurology. 2000, 55: 480-483.PubMed Du Y, Dodel RC, Eastwood BJ, Bales KR, Gao F, Lohmuller F: Association of an interleukin 1 alpha polymorphism with Alzheimer's disease. Neurology. 2000, 55: 480-483.PubMed
80.
go back to reference Grimaldi LM, Casadei VM, Ferri C, Veglia F, Licastro F, Annoni G: Association of early-onset ALzhaeimer's disease with an interleukin-1alpha gene polymorphism. Ann Neurol. 2000, 47: 361-365. 10.1002/1531-8249(200003)47:3<361::AID-ANA12>3.3.CO;2-E.PubMed Grimaldi LM, Casadei VM, Ferri C, Veglia F, Licastro F, Annoni G: Association of early-onset ALzhaeimer's disease with an interleukin-1alpha gene polymorphism. Ann Neurol. 2000, 47: 361-365. 10.1002/1531-8249(200003)47:3<361::AID-ANA12>3.3.CO;2-E.PubMed
81.
go back to reference Gibson AW, Edberg JC, Wu J, Westendorp RG, Huizinga TW, Kimberly RP: Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of sytemic lupus erythematosus. J Immunol. 2001, 166: 3915-3922.PubMed Gibson AW, Edberg JC, Wu J, Westendorp RG, Huizinga TW, Kimberly RP: Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of sytemic lupus erythematosus. J Immunol. 2001, 166: 3915-3922.PubMed
82.
go back to reference Tsuchiya N, Ohashi J, Tokunaga K: Variations in immune response genes and their associations with multifactorial immune disorders. Immunol Rev. 2002, 190: 169-181. 10.1034/j.1600-065X.2002.19013.x.PubMed Tsuchiya N, Ohashi J, Tokunaga K: Variations in immune response genes and their associations with multifactorial immune disorders. Immunol Rev. 2002, 190: 169-181. 10.1034/j.1600-065X.2002.19013.x.PubMed
83.
go back to reference Yucesoy B, Kashon ML, Luster MI: Cytokine polymorphisms in chronic inflammatory diseases with referece to occupational diseases. Curr Mol Med. 2003, 3: 39-48.PubMed Yucesoy B, Kashon ML, Luster MI: Cytokine polymorphisms in chronic inflammatory diseases with referece to occupational diseases. Curr Mol Med. 2003, 3: 39-48.PubMed
84.
go back to reference Howell WM, Calder PC, Grimble RF: Gene polymorphisms, inflammatory diseases and cancer. Proc Nutr Soc. 2002, 61: 447-456. 10.1079/PNS2002186.PubMed Howell WM, Calder PC, Grimble RF: Gene polymorphisms, inflammatory diseases and cancer. Proc Nutr Soc. 2002, 61: 447-456. 10.1079/PNS2002186.PubMed
85.
go back to reference Yucesoy B, Vallyathan V, Landsittel DP, Simeonova P, Luster MI: Cytokine polymorphisms in silicosis and other pneumoconioses. Mol Cell Biochem. 2002, 234–235: 219-224. 10.1023/A:1015987007360.PubMed Yucesoy B, Vallyathan V, Landsittel DP, Simeonova P, Luster MI: Cytokine polymorphisms in silicosis and other pneumoconioses. Mol Cell Biochem. 2002, 234–235: 219-224. 10.1023/A:1015987007360.PubMed
86.
go back to reference Balasubramanian SP, Brown NJ, Reed MW: Role of genetic polymorphisms in tumour angiogenesis. Br J Cancer. 2002, 87: 1057-1065. 10.1038/sj.bjc.6600625.PubMedCentralPubMed Balasubramanian SP, Brown NJ, Reed MW: Role of genetic polymorphisms in tumour angiogenesis. Br J Cancer. 2002, 87: 1057-1065. 10.1038/sj.bjc.6600625.PubMedCentralPubMed
87.
go back to reference Vercelli D: Genetics of IL-13 and functional relevance of IL-13 variants. Curr Opin Allergy Clin Immunol. 2002, 2: 389-393. 10.1097/00130832-200210000-00004.PubMed Vercelli D: Genetics of IL-13 and functional relevance of IL-13 variants. Curr Opin Allergy Clin Immunol. 2002, 2: 389-393. 10.1097/00130832-200210000-00004.PubMed
88.
go back to reference McGeer PL, McGeer EG: Polymorphisms of inflammatory genes and the risk of Alzheimer disease. Arch Neurol. 2001, 58: 1790-1792. 10.1001/archneur.58.11.1790.PubMed McGeer PL, McGeer EG: Polymorphisms of inflammatory genes and the risk of Alzheimer disease. Arch Neurol. 2001, 58: 1790-1792. 10.1001/archneur.58.11.1790.PubMed
89.
go back to reference Andreotti F, Porto I, Crea F, Maseri A: Inflammatory gene polymorphisms and ischaemic heart disease: review of population association studies. Heart. 2002, 87: 107-112. 10.1136/heart.87.2.107.PubMedCentralPubMed Andreotti F, Porto I, Crea F, Maseri A: Inflammatory gene polymorphisms and ischaemic heart disease: review of population association studies. Heart. 2002, 87: 107-112. 10.1136/heart.87.2.107.PubMedCentralPubMed
90.
go back to reference Holler E: Cytokines, viruses, and graft-versus-host disease. Curr Opin Hematol. 2002, 9: 479-484. 10.1097/00062752-200211000-00002.PubMed Holler E: Cytokines, viruses, and graft-versus-host disease. Curr Opin Hematol. 2002, 9: 479-484. 10.1097/00062752-200211000-00002.PubMed
91.
go back to reference Marder B, Schroppel B, Murphy B: Genetic variability and transplantation. Curr Opin Urol. 2003, 13: 81-89. 10.1097/00042307-200303000-00001.PubMed Marder B, Schroppel B, Murphy B: Genetic variability and transplantation. Curr Opin Urol. 2003, 13: 81-89. 10.1097/00042307-200303000-00001.PubMed
92.
go back to reference Haukim N, Bidwell JL, Smith AJP, Keen LJ, Gallagher G, Kimberly R: Cytokine gene polymorphism in human disease: on-line databases, Supplement 2. Genes Immun. 2002, 3: 313-330. 10.1038/sj.gene.6363881.PubMed Haukim N, Bidwell JL, Smith AJP, Keen LJ, Gallagher G, Kimberly R: Cytokine gene polymorphism in human disease: on-line databases, Supplement 2. Genes Immun. 2002, 3: 313-330. 10.1038/sj.gene.6363881.PubMed
93.
go back to reference Daly AK, Day CP, Donaldson PT: Polymorphisms of immunoregulatory genes: towards individualized immunosuppressive therapy?. Am J Pharmocogenomics. 2002, 2: 13-23. Daly AK, Day CP, Donaldson PT: Polymorphisms of immunoregulatory genes: towards individualized immunosuppressive therapy?. Am J Pharmocogenomics. 2002, 2: 13-23.
94.
go back to reference Wang E, Adams S, Zhao Y, Panelli MC, Simon R, Klein H: A strategy for detection of known and unknown SNP using a minimum number of oligonucleotides. J Transl Med. 2003, 1: 4-10.1186/1479-5876-1-4.PubMedCentralPubMed Wang E, Adams S, Zhao Y, Panelli MC, Simon R, Klein H: A strategy for detection of known and unknown SNP using a minimum number of oligonucleotides. J Transl Med. 2003, 1: 4-10.1186/1479-5876-1-4.PubMedCentralPubMed
95.
go back to reference O'Neill LA, Fitzgerald KA, Bowie AG: The Toll-IL-1 receptor adaptor family grows to five members. Trends Immunol. 2003, 24: 286-290. 10.1016/S1471-4906(03)00115-7.PubMed O'Neill LA, Fitzgerald KA, Bowie AG: The Toll-IL-1 receptor adaptor family grows to five members. Trends Immunol. 2003, 24: 286-290. 10.1016/S1471-4906(03)00115-7.PubMed
96.
go back to reference O'Neill LA, Brown Z, Ward SG: Toll-like receptors in the spotlight. Nat Immunol. 2003, 4: 299-10.1038/ni0403-299.PubMed O'Neill LA, Brown Z, Ward SG: Toll-like receptors in the spotlight. Nat Immunol. 2003, 4: 299-10.1038/ni0403-299.PubMed
97.
go back to reference Beutler B: Tlr4: central component of the sole mammalian LPS sensor. Curr Opin Immunol. 2000, 12: 20-26. 10.1016/S0952-7915(99)00046-1.PubMed Beutler B: Tlr4: central component of the sole mammalian LPS sensor. Curr Opin Immunol. 2000, 12: 20-26. 10.1016/S0952-7915(99)00046-1.PubMed
98.
go back to reference Anderson KV: Toll signaling pathways in the innate immune response. Curr Opin Immunol. 2000, 12: 13-19. 10.1016/S0952-7915(99)00045-X.PubMed Anderson KV: Toll signaling pathways in the innate immune response. Curr Opin Immunol. 2000, 12: 13-19. 10.1016/S0952-7915(99)00045-X.PubMed
99.
go back to reference Takeda K, Kaisho T, Akira S: Toll-like receptors. Annu Rev Immunol. 2003, 21: 335-376. 10.1146/annurev.immunol.21.120601.141126.PubMed Takeda K, Kaisho T, Akira S: Toll-like receptors. Annu Rev Immunol. 2003, 21: 335-376. 10.1146/annurev.immunol.21.120601.141126.PubMed
100.
go back to reference Hatada EN, Krappmann D, Scheidereit C: NF-k B and the innate immune response. Curr Opin I. 2000, 12: 52-58. 10.1016/S0952-7915(99)00050-3. Hatada EN, Krappmann D, Scheidereit C: NF-k B and the innate immune response. Curr Opin I. 2000, 12: 52-58. 10.1016/S0952-7915(99)00050-3.
101.
go back to reference Blackwell TS, Christman JW: The role of nuclear factor-kappa B in cytokine gene regulation. Am J Respir Cell Mol Biol. 1997, 17: 3-9.PubMed Blackwell TS, Christman JW: The role of nuclear factor-kappa B in cytokine gene regulation. Am J Respir Cell Mol Biol. 1997, 17: 3-9.PubMed
102.
go back to reference Hanada T, Yoshimura A: Regulation of cytokine signaling and inflammation. Cytokine Growth Factor Rev. 2002, 13: 413-421. 10.1016/S1359-6101(02)00026-6.PubMed Hanada T, Yoshimura A: Regulation of cytokine signaling and inflammation. Cytokine Growth Factor Rev. 2002, 13: 413-421. 10.1016/S1359-6101(02)00026-6.PubMed
103.
go back to reference Abraham E: Nuclear factor-kappa B and its role in sepsis-associated organ failure. J Infect Dis. 2003, 187: S364-S369. 10.1086/374750.PubMed Abraham E: Nuclear factor-kappa B and its role in sepsis-associated organ failure. J Infect Dis. 2003, 187: S364-S369. 10.1086/374750.PubMed
104.
go back to reference Wajant H, Scheurich P: Tumor necrosis factor receptor-associated factor (TRAF) 2 and its role in TNF signaling. Int J Biochem Cell Biol. 2001, 33: 19-32. 10.1016/S1357-2725(00)00064-9.PubMed Wajant H, Scheurich P: Tumor necrosis factor receptor-associated factor (TRAF) 2 and its role in TNF signaling. Int J Biochem Cell Biol. 2001, 33: 19-32. 10.1016/S1357-2725(00)00064-9.PubMed
105.
go back to reference Wajant H: The Fas signaling pathway: more than a paradigm. Science. 2002, 296: 1635-1636. 10.1126/science.1071553.PubMed Wajant H: The Fas signaling pathway: more than a paradigm. Science. 2002, 296: 1635-1636. 10.1126/science.1071553.PubMed
106.
go back to reference Bradley JR, Pober JS: Tumor necrosis factor receptor-associated factors (TRAFs). Oncogene. 2001, 20: 6482-6491. 10.1038/sj.onc.1204788.PubMed Bradley JR, Pober JS: Tumor necrosis factor receptor-associated factors (TRAFs). Oncogene. 2001, 20: 6482-6491. 10.1038/sj.onc.1204788.PubMed
107.
go back to reference Wajant H, Pfizenmaier K, Scheurich P: TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy. Apoptosis. 2002, 7: 449-459. 10.1023/A:1020039225764.PubMed Wajant H, Pfizenmaier K, Scheurich P: TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy. Apoptosis. 2002, 7: 449-459. 10.1023/A:1020039225764.PubMed
108.
go back to reference Wajant H, Pfizenmaier K, Scheurich P: Tumor necrosis factor signaling. Cell Death Differ. 2003, 10: 45-65. 10.1038/sj.cdd.4401189.PubMed Wajant H, Pfizenmaier K, Scheurich P: Tumor necrosis factor signaling. Cell Death Differ. 2003, 10: 45-65. 10.1038/sj.cdd.4401189.PubMed
109.
go back to reference Chee M, Yang R, Hubbell E, Berno A, Xiaohua C, Stern D: Accessing genetic information with high-density DNA arrays. Science. 1996, 274: 610-614. 10.1126/science.274.5287.610.PubMed Chee M, Yang R, Hubbell E, Berno A, Xiaohua C, Stern D: Accessing genetic information with high-density DNA arrays. Science. 1996, 274: 610-614. 10.1126/science.274.5287.610.PubMed
110.
go back to reference Hacia JG, Brody LC, Chee MS, Fodor SP, Collins FS: Detection of heterozygous mutations in BRCA1 using high density oligonucleotide arrays and two-colour fluorescence analysis [see comments]. Nat Genet. 1996, 14: 441-447.PubMed Hacia JG, Brody LC, Chee MS, Fodor SP, Collins FS: Detection of heterozygous mutations in BRCA1 using high density oligonucleotide arrays and two-colour fluorescence analysis [see comments]. Nat Genet. 1996, 14: 441-447.PubMed
111.
go back to reference Saiki RK, Walsh PS, Levenson CH, Erlich HA: Genetic analysis of amplified DNA with immobilized sequence-specific oligonucleotide probes. Proc Natl Acad Sci U S A. 1989, 86: 6230-6234.PubMedCentralPubMed Saiki RK, Walsh PS, Levenson CH, Erlich HA: Genetic analysis of amplified DNA with immobilized sequence-specific oligonucleotide probes. Proc Natl Acad Sci U S A. 1989, 86: 6230-6234.PubMedCentralPubMed
112.
go back to reference Lockhart DJ, Dong H, Byrne MC, Folliette MT, Gallo MV, Chee MS: Expression monitoring of hybridization to high-density oligonucleotide arrays. Nature Biotechnol. 1996, 14: 1675-1680. Lockhart DJ, Dong H, Byrne MC, Folliette MT, Gallo MV, Chee MS: Expression monitoring of hybridization to high-density oligonucleotide arrays. Nature Biotechnol. 1996, 14: 1675-1680.
113.
go back to reference Chen J, Iannone MA, Li M-S, Taylor JD, Rivers P, Nelsen AJ: A microsphere-based assay for multiplex single nucleotide polymorphism analysis using single base chain extension. Genome Res. 2000, 10: 549-557. 10.1101/gr.10.4.549.PubMedCentralPubMed Chen J, Iannone MA, Li M-S, Taylor JD, Rivers P, Nelsen AJ: A microsphere-based assay for multiplex single nucleotide polymorphism analysis using single base chain extension. Genome Res. 2000, 10: 549-557. 10.1101/gr.10.4.549.PubMedCentralPubMed
114.
go back to reference Tong AK, Ju J: Single nucleotide polymorphism detection by combinatorial fluorescence energy transfer tags and biotinylated dideoxynucleotides. Nucleic Acids Res. 2002, 30: e19-10.1093/nar/30.5.e19.PubMedCentralPubMed Tong AK, Ju J: Single nucleotide polymorphism detection by combinatorial fluorescence energy transfer tags and biotinylated dideoxynucleotides. Nucleic Acids Res. 2002, 30: e19-10.1093/nar/30.5.e19.PubMedCentralPubMed
115.
go back to reference Kwok P-Y: High-throughput genotyping assay approaches. Pharmacogenomics. 2000, 1: 95-100.PubMed Kwok P-Y: High-throughput genotyping assay approaches. Pharmacogenomics. 2000, 1: 95-100.PubMed
116.
go back to reference Chee MC, Yang R, Hubbell E, rno A, uang XC, Stern D: Assessing genetic information with high-density DNA arrays. Science. 1996, 274: 610-614. 10.1126/science.274.5287.610.PubMed Chee MC, Yang R, Hubbell E, rno A, uang XC, Stern D: Assessing genetic information with high-density DNA arrays. Science. 1996, 274: 610-614. 10.1126/science.274.5287.610.PubMed
117.
go back to reference Guo Z, Gatterman MS, Hood L, Hansen JA, Petersdorf EW: Oligonucleotide arrays for high-throughput SNPs detection in the MHC class I genes: HLA-B as a model system. Genome Res. 2002, 12: 447-457. 10.1101/gr.206402. Article published online before print in February 2002.PubMedCentralPubMed Guo Z, Gatterman MS, Hood L, Hansen JA, Petersdorf EW: Oligonucleotide arrays for high-throughput SNPs detection in the MHC class I genes: HLA-B as a model system. Genome Res. 2002, 12: 447-457. 10.1101/gr.206402. Article published online before print in February 2002.PubMedCentralPubMed
118.
go back to reference Hacia JG: Resequencing and mutational analysis using oligonucleotide microarrays. Nature Genetics. 1999, 21: 42-47. 10.1038/4469.PubMed Hacia JG: Resequencing and mutational analysis using oligonucleotide microarrays. Nature Genetics. 1999, 21: 42-47. 10.1038/4469.PubMed
119.
go back to reference Hacia JG, Sun B, Hunt N, Edgemon K, Mosbrook D, Robbins C: Strategies for mutational analysis of the large multiexon ATM gene using high-density oligonucleotide arrays. Genome Res. 1998, 8: 1245-1258.PubMed Hacia JG, Sun B, Hunt N, Edgemon K, Mosbrook D, Robbins C: Strategies for mutational analysis of the large multiexon ATM gene using high-density oligonucleotide arrays. Genome Res. 1998, 8: 1245-1258.PubMed
120.
go back to reference Fodor SP, Read JL, Pirrung MC, Stryer L, Lu AT, Solas D: Light-directed, spatially addressable parallel chemical synthesis. Science. 1991, 251: 767-773.PubMed Fodor SP, Read JL, Pirrung MC, Stryer L, Lu AT, Solas D: Light-directed, spatially addressable parallel chemical synthesis. Science. 1991, 251: 767-773.PubMed
121.
go back to reference Okamoto T, Suzuki T, Yamamoto N: Microarray fabrication with covalent attachment of DNA using Bubble Jet technology. Nature Biotech. 2000, 18: 438-441. 10.1038/74507. Okamoto T, Suzuki T, Yamamoto N: Microarray fabrication with covalent attachment of DNA using Bubble Jet technology. Nature Biotech. 2000, 18: 438-441. 10.1038/74507.
122.
go back to reference Goto S, Takahashi A, Kamisango K, Matsubara K: Single-nucleotide polymorphism analysis by hybridization protection assay on solid support. Analytical Biochemistry. 2002, 307: 25-32. 10.1016/S0003-2697(02)00019-2.PubMed Goto S, Takahashi A, Kamisango K, Matsubara K: Single-nucleotide polymorphism analysis by hybridization protection assay on solid support. Analytical Biochemistry. 2002, 307: 25-32. 10.1016/S0003-2697(02)00019-2.PubMed
123.
go back to reference Dumur CI, Dechsukhum C, Ware JL, Cofield SS, Best AM, Wilkinson DS: Genome-wide detection of LOH in prostate cancer using human SNP microarray technology. Genomics. 2003, 81: 260-269. 10.1016/S0888-7543(03)00020-X.PubMed Dumur CI, Dechsukhum C, Ware JL, Cofield SS, Best AM, Wilkinson DS: Genome-wide detection of LOH in prostate cancer using human SNP microarray technology. Genomics. 2003, 81: 260-269. 10.1016/S0888-7543(03)00020-X.PubMed
124.
go back to reference Lu ML, Wikman F, Orntoft TF, Charytonowicz E, Rabbani F, Zhang Z: Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods. Clin Cancer Res. 2002, 8: 171-179.PubMed Lu ML, Wikman F, Orntoft TF, Charytonowicz E, Rabbani F, Zhang Z: Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods. Clin Cancer Res. 2002, 8: 171-179.PubMed
125.
go back to reference Lotze MT, Matory YL, Rayner AA, Ettinghausen SE, Vetto JT, Seipp CA: Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer. 1986, 58: 2764-2772.PubMed Lotze MT, Matory YL, Rayner AA, Ettinghausen SE, Vetto JT, Seipp CA: Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer. 1986, 58: 2764-2772.PubMed
126.
go back to reference MacFarlane MP, Yang JC, Guleria AS, White RLJ, Seipp CA, Einhorn JH: The hematologic toxicity of interleukin-2 in patients with metastatic melanoma and renal cell carcinoma. Cancer. 1995, 75: 1030-1037.PubMed MacFarlane MP, Yang JC, Guleria AS, White RLJ, Seipp CA, Einhorn JH: The hematologic toxicity of interleukin-2 in patients with metastatic melanoma and renal cell carcinoma. Cancer. 1995, 75: 1030-1037.PubMed
127.
go back to reference White RLJ, Schwartzentruber D, Guleria AS, McFarlane MP, White DE, ucker E: Cardiopulmonary toxicity of treatment with high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma. Cancer. 1994, 74: 3212-3222.PubMed White RLJ, Schwartzentruber D, Guleria AS, McFarlane MP, White DE, ucker E: Cardiopulmonary toxicity of treatment with high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma. Cancer. 1994, 74: 3212-3222.PubMed
128.
go back to reference Kammula US, White DE, Rosenberg SA: Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer. 1998, 83: 797-805. 10.1002/(SICI)1097-0142(19980815)83:4<797::AID-CNCR25>3.3.CO;2-2.PubMed Kammula US, White DE, Rosenberg SA: Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer. 1998, 83: 797-805. 10.1002/(SICI)1097-0142(19980815)83:4<797::AID-CNCR25>3.3.CO;2-2.PubMed
129.
go back to reference Royal RE, Steinberg SM, Krouse SE, Heywood G, White DE, Hwu P: Correlates of Response to il-2 therapy in patients treated for metastatic renal cancer and melanoma. Cancer J Sci Am. 1996, 2: 91-98.PubMed Royal RE, Steinberg SM, Krouse SE, Heywood G, White DE, Hwu P: Correlates of Response to il-2 therapy in patients treated for metastatic renal cancer and melanoma. Cancer J Sci Am. 1996, 2: 91-98.PubMed
130.
go back to reference Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K: High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1998, 17: 2105-2116. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K: High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1998, 17: 2105-2116.
131.
go back to reference Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA: Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol. 2001, 19: 3477-3482.PubMed Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA: Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol. 2001, 19: 3477-3482.PubMed
132.
go back to reference Panelli MC, Wang E, Phan G, Puhlman M, Miller L, Ohnmacht GA: Genetic profiling of peripharal mononuclear cells and melanoma metastases in response to systemic interleukin-2 administration. Genome Biol. 2002, 3: RESEARCH0035-10.1186/gb-2002-3-7-research0035.PubMedCentralPubMed Panelli MC, Wang E, Phan G, Puhlman M, Miller L, Ohnmacht GA: Genetic profiling of peripharal mononuclear cells and melanoma metastases in response to systemic interleukin-2 administration. Genome Biol. 2002, 3: RESEARCH0035-10.1186/gb-2002-3-7-research0035.PubMedCentralPubMed
133.
go back to reference Panelli MC, Martin B, Nagorsen D, Wang E, Smith K, Monsurro' V: A genomic and proteomic-based hypothesis on the eclectic effects of systemic interleukin-2 admnistration in the context of melanoma-specific immunization. J Invest Dermatol. 2003, Panelli MC, Martin B, Nagorsen D, Wang E, Smith K, Monsurro' V: A genomic and proteomic-based hypothesis on the eclectic effects of systemic interleukin-2 admnistration in the context of melanoma-specific immunization. J Invest Dermatol. 2003,
Metadata
Title
Polymorphism in clinical immunology – From HLA typing to immunogenetic profiling
Authors
Ping Jin
Ena Wang
Publication date
01-06-2003
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2003
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-1-8

Other articles of this Issue 1/2003

Journal of Translational Medicine 1/2003 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.